

04-70450-26

Original Effective Date: 05/15/18

Reviewed: 02/23/23

Revised: 09/30/23

Subject: Computed Tomography (CT) Heart

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions	Related Guidelines
Other	References	Update			

DESCRIPTION:

Computed tomography (CT) heart (cardiac CT) can be used to evaluate the anatomy and pathology of the pericardium and cardiac chambers and assessment of the central great vessels and heart function, including the cardiac valves. Cardiac CT is also useful in detecting and characterizing cardiac and pericardial disorders, such as masses and pericardial fluid. CT is a form of medical imaging that involves the exposure of patients to ionizing radiation. CT should only be performed under the supervision of a physician with training in radiation protection to optimize examination safety. Radiation exposure should be taken into account when considering the use of this technology. This guideline addresses the use of heart CT in the outpatient setting.

POSITION STATEMENT:

Cardiac computed tomography (heart CT) **meets the definition of medical necessity** for the following indications:

Congenital heart disease

- Congenital lesions: prior to planned repair and for change in clinical status and/or new concerning signs or symptoms
- Patent ductus arteriosus: routine surveillance (1-2 years) in a member with postprocedural aortic obstruction
- Aortic stenosis or regurgitation: routine surveillance (6-12 months) in a child with aortic sinus and/or ascending aortic dilation with increasing size
- Aortic coarctation and interrupted aortic arch:

- Routine surveillance (3–5 years) in a child or adult with mild aortic coarctation
- Post procedure (surgical or catheter-based) routine surveillance (3–5 years) in an asymptomatic member to evaluate for aortic arch aneurysms, in-stent stenosis, stent fracture, or endoleak
- Tetralogy of Fallot:
 - Routine surveillance (2–3 years) in a member with valvular or ventricular dysfunction, right ventricular outflow tract obstruction, branch pulmonary artery stenosis, arrhythmias, or presence of a right ventricle to pulmonary artery (RV-to-PA) conduit
- D-Loop transposition of the great arteries (post-operative):
 - Routine surveillance (3–5 years) in an asymptomatic member
 - Routine surveillance (1–2 years) in a member with dilated aortic root with increasing size, or aortic regurgitation
 - Routine surveillance (3–12 months) in a member with \geq moderate systemic aortic valve (AV) regurgitation, systemic right ventricular (RV) dysfunction, left ventricular outflow tract (LVOT) obstruction, or arrhythmias
- Congenitally corrected transposition of the great arteries:
 - Unrepaired: routine surveillance (3–5 years) in an asymptomatic member
 - Postoperative: routine surveillance (3–5 years) in an asymptomatic member
 - Postoperative anatomic repair: routine surveillance (6–12 months) in a member with valvular or ventricular dysfunction, right or left ventricular outflow tract obstruction, or presence of a right ventricle to pulmonary artery (RV-to-PA) conduit
 - Postoperative physiological repair with VSD closure and/or LV-to-PA conduit: routine surveillance (3–12 months) in a member with \geq moderate systemic AV valve regurgitation, systemic RV dysfunction, and/or LV-to-PA conduit dysfunction
- Truncus arteriosus: routine surveillance (1–2 years) in an asymptomatic child or adult with \geq moderate truncal stenosis and/or regurgitation
- Single-ventricle heart disease: post-operative routine surveillance (3–5 years) in an asymptomatic member.

Note: For the above indications, either computed tomography (CT) or cardiac magnetic resonance imaging (CMR) may be performed.

Cardiomyopathy

- Quantification of myocardial (muscle) mass (computed tomography (CT) or cardiac magnetic resonance (CMR))
- Assessment of right ventricular morphology in suspected arrhythmogenic right ventricular cardiomyopathy, based upon other findings such as:
 - Nonsustained ventricular tachycardia (VT)
 - Unexplained syncope

- Electrocardiogram (ECG) abnormalities
- First-degree relative with positive genotype of arrhythmogenic right ventricular cardiomyopathy (ARVC).

Valvular heart disease

- Characterization of native or prosthetic valves with clinical signs or symptoms suggesting valve dysfunction, when transthoracic echocardiogram (TTE), transesophageal echocardiogram (TEE) and/or fluoroscopy have been inadequate.
- Evaluation of right ventricular (RV) function in severe tricuspid regurgitation (TR), including systolic and diastolic volumes when transthoracic echocardiogram (TTE) images are inadequate and cardiac magnetic resonance (CMR) is not readily available.
- Pulmonary hypertension in the absence of valvular disease.
- Evaluation of suspected infective endocarditis with moderate to high pretest probability (i.e. staph bacteremia, fungemia, prosthetic heart valve, intracardiac device) when transthoracic echocardiogram (TTE) and transesophageal echocardiogram (TEE) have been inadequate.
- Evaluation of suspected paravalvular infections when the anatomy cannot be clearly delineated by transthoracic echocardiogram (TTE) and transesophageal echocardiogram (TE).

Evaluation of intra and extracardiac structures

- Evaluation of cardiac mass, suspected tumor or thrombus, or cardiac source of emboli including valvular mass or vegetation when imaging with transthoracic echocardiogram (TTE) and transesophageal echocardiogram (TEE) have been inadequate
- Re-evaluation of prior findings for interval change when a change in therapy is anticipated
- Evaluation of pericardial anatomy, when transthoracic echocardiogram (TTE) and/or transesophageal echocardiogram (TEE) are inadequate.

Electrophysiologic procedure planning

- Evaluation of pulmonary venous anatomy prior to radiofrequency ablation of atrial fibrillation.
- For follow up when needed for evaluation of pulmonary vein stenosis
- Non-invasive coronary vein mapping prior to placement of biventricular pacing leads.

Transcatheter structural intervention planning

- Evaluation for transcatheter aortic valve replacement (TAVR)
- When transthoracic echocardiogram (TTE) and transesophageal echocardiogram (TEE) cannot provide adequate imaging, CT imaging can be used for planning: robotic mitral valve repair, atrial septal defect closure, left atrial appendage closure, ventricular septal defect closure, endovascular grafts, and percutaneous pulmonic valve implantation
- Evaluation for suitability of transcatheter mitral valve procedures alone or in addition to TEE.

Aortic pathology

- Computed tomography (CT), magnetic resonance (MR) or echocardiogram can be used for screening and follow up with CT and MR preferred for imaging beyond the proximal ascending thoracic aorta for the following:
 - Evaluation of dilated aortic sinuses or ascending aorta identified by TTE
 - Suspected acute aortic pathology, such as dissection
 - Screening first degree relatives of members with a history of thoracic aortic aneurysm or dissection or an associated high-risk mutation for thoracic aneurysm in common
 - Screening second degree relative of a member with thoracic aortic aneurysm when the first degree relative has aortic dilation, aneurysm, or dissection
 - Six months follow up after initial finding of a dilated thoracic aorta, for assessment of rate of change
 - Annual follow up of enlarged thoracic aorta that is above top normal for age, gender, and size up to 4.4 cm
 - Biannual (twice/yr.) follow up of enlarged aortic root ≥ 4.5 cm (> 4.5 cm for bicuspid aortic valve) or showing growth rate ≥ 0.5 cm/year.
- Members with Marfan may undergo annual imaging with CT, MRI or TTE with increase to biannual (twice-yearly) when diameter ≥ 4.5 cm or when expansions is > 0.5 cm/yr
- Members with Turner's syndrome should undergo initial imaging with (CT, MRI or TTE, for evidence of dilatation of the ascending thoracic aorta. If imaging is normal and there are no risk factors for aortic dissection, repeat imaging should be performed every 5-10 years or if otherwise indicated. If the aorta is enlarged, appropriate follow-up imaging should be done according to size, as noted above.
- Evaluation of the aorta in the setting of a known or suspected connective tissue disease or genetic condition that predisposes to aortic aneurysm or dissection (i.e. Loeys-Dietz, Ehlers-Danlos), with re-evaluation at 6 months for rate of expansion. Complete evaluation with CMR from the cerebrovascular circulation to the pelvis is recommended with Loeys-Dietz syndrome.

Suggested Follow-up of Aortic Pathologies After Repair or Treatment

Pathology	Interval	Study
Acute dissection	Before discharge, 1 mo., 6 mo., yearly	CT or MR, chest plus abdomen TTE
Chronic dissection	Before discharge, 1 y., 2 to 3 y.	CT or MR, chest plus abdomen TTE
Aortic root repair	Before discharge, yearly	TTE
AVR plus ascending	Before discharge, yearly	TTE
Aortic arch	Before discharge, 1 y. 2 to 3 y.	CT or MR, chest plus abdomen
Thoracic aortic stent	Before discharge, 1 mo., 2 mo., 6 mo., yearly or 30 days*	CXR, CT, chest plus abdomen

Acute IMH/PAU	Before discharge, 1 mo., 3 mo., yearly	CT or MR, chest plus abdomen
---------------	--	------------------------------

*US Food and Drug Administration stent graft studies usually required before discharge or at 30-day CT scan to detect endovascular leaks. If there is concern about a leak, a pre-discharge study is recommended; however, the risk of renal injury should be borne in mind. All patients should be receiving beta blockers after surgery or medically managed aortic dissection, if tolerated. Adapted from: Erbel et al (359)

Abbreviations: AVR: aortic valve replacement; CT: computed tomographic imaging; CXR: chest x-ray; IMH: intramural hematoma; MR: magnetic resonance imaging; PAU: penetrating atherosclerotic ulcer; TTE: transthoracic echocardiography

Adapted from Erbel R, Alfonso F, Boileau C, et al. Diagnosis and management of aortic dissection. Eur Heart J. 2001;22:1642–81.

BILLING/CODING INFORMATION:

CPT Coding:

75572	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)
75573	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of left ventricular [LV] cardiac function, right ventricular [RV] structure and function and evaluation of venous structures, if performed)

REIMBURSEMENT INFORMATION:

Request for a follow-up study

A follow-up study may be needed to help evaluate a patient's progress after treatment, procedure, intervention or surgery. Documentation requires a medical reason that clearly indicates why additional imaging is needed for the type and area(s) requested.

LOINC Codes:

The following information may be required documentation to support medical necessity: physician history and physical, physician progress notes, plan of treatment, laboratory studies and reason for computed tomography (heart CT).

Documentation Table	LOINC Codes	LOINC Time Frame Modifier Code	LOINC Time Frame Modifier Codes Narrative
---------------------	-------------	--------------------------------	---

Physician history and physical	28626-0	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Attending physician progress note	18741-9	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Plan of treatment	18776-5	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Radiology reason for study	18785-6	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Radiology comparison study-date and time	18779-9	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Radiology comparison study observation	18834-2	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Radiology-study observation	18782-3	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Radiology-impression	19005-8	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Radiology study-recommendation (narrative)	18783-1	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim

PROGRAM EXCEPTIONS:

Federal Employee Plan (FEP): Follow FEP guidelines.

Medicare Advantage products

The following Local Coverage Determination (LCD) was reviewed on the last guideline revised date: Computed Tomographic Angiography of the Chest, Heart and Coronary Arteries, (L33282) located at fcso.com.

No National Coverage Determination (NCD) was found at the time of the last guideline reviewed date.

DEFINITIONS:

No guideline specific definitions apply.

RELATED GUIDELINES:

[Computed Tomography to Detect Coronary Artery Calcification, 04-70450-02](#)

[Computed Tomographic Angiography \(CTA\) Heart, 04-70540-03](#)

OTHER:

Other names used to report computed tomography (CT Heart):

Cardiac Computed Tomography (CT)

Cardiac CT

REFERENCES:

1. Baumgartner H, Bonhoeffer P, De Groot NM et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010 Dec;31(23):2915-2957.
2. Baumgartner H, Falk V, Bax JJ et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. European Heart Journal 2017; 38: 2739-2791.
3. Benza R, Biederman R, Murali S et al. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2008 Nov 18;52(21):1683-1692.
4. Bhawe NM, Nienaber CA, Clough RE et al. Multimodality Imaging of Thoracic Aortic Diseases in Adults. JACC Cardiovasc Imaging. 2018 Jun;11(6):902-919.
5. Cikach F, Desai MY, Roselli EE et al. Thoracic aortic aneurysm: How to counsel, when to refer. Cleve Clin J Med. 2018 Jun;85(6):481-492.
6. Clavel MA, Burwash IG, Pibarot P. Cardiac Imaging for Assessing Low-Gradient Severe Aortic Stenosis. JACC Cardiovasc Imaging. 2017 Feb;10(2):185-202.
7. Cohen MS, Eidem BW, Cetta F et al. Multimodality imaging guidelines of patients with transposition of the great arteries: a report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2016 Jul;29(7):571-621.
8. Datta J, White CS, Gikeson RC et al. Anomalous Coronary Arteries in Adults: Depiction at Multi-Detector Row CT Angiography. Radiology 2005; 235(3): 812 – 818.
9. Doherty JU, Kort S, Mehran R et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for Multimodality Imaging in Valvular Heart Disease: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and

Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *J Nucl Cardiol*. 2017 Dec; 24(6):2043-2063.

10. Douglas PS, Garcia MJ, Haines DE et al. ACCF/AHA/ASA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *Journal of the American College of Cardiology* 2011; 57 (9): 1126-1166.
11. Dupont MV, Drăgean CA, Coche EE. Right ventricle function assessment by MDCT. *AJR Am J Roentgenol*. 2011 Jan;196(1):77-86.
12. Erbel R, Alfonso F, Boileau C et al. Diagnosis and management of aortic dissection. *Eur Heart J*. 2001 Sep;22(18):1642-81. Fihn SD, Blankenship JC, Alexander KP et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Journal of the American College of Cardiology* 2014; 64 (18): 1929-1949.
13. Flachskampf FA, Wouters PF, Edvardsen T et al. Recommendations for transoesophageal echocardiography: EACVI update 2014. *Eur Heart J Cardiovasc Imaging*. 2014 Apr;15(4):353-365.
14. Goldfinger JZ, Halperin JL1, Marin ML et al. Thoracic aortic aneurysm and dissection. *J Am Coll Cardiol*. 2014 Oct 21;64(16):1725-1739.
15. Haddad F, Hunt SA, Rosenthal DN et al. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. *Circulation*. 2008 Mar 18;117(11):1436-1448.
16. Hendel RC, Patel MR, Kramer CM et al. ACCF/ACR/SCCT/SCMR/ ASNC/NASCI/SCAI/SIR 2006 Appropriateness Criteria for Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging-A Report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. *Journal of the American College of Cardiology* 2006; 48(7): 1475 – 1497.
17. Hiratzka LF, Bakris GL, Beckman JA et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. *J Am Coll Cardiol*. 2010 Apr 6;55(14): e27-e129.
18. Hiratzka LF, Creager MA, Isselbacher EM et al. Surgery for aortic dilatation in patients with bicuspid aortic valves: a statement of clarification from the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2016 Feb 16;67(6):724-731.

19. Kassop D, Donovan MS, Cheezum MK et al. Cardiac Masses on Cardiac CT: A Review. *Curr Cardiovasc Imaging Rep.* 2014;7:9281.
20. Klein AL, Abbata S, Agler DA et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. *J Am Soc Echocardiogr.* 2013 Sep;26(9):965-1012.e15.
21. Marcus FI, McKenna WJ, Sherrill D et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. *Eur Heart J.* 2010 Apr;31(7):806-814.
22. Orwat S, Diller GP, Baumgartner H. Imaging of congenital heart disease in adults: choice of modalities. *Eur Heart J Cardiovasc Imaging.* 2014 Jan;15(1):6-17. Otto CM, Kumbhani DJ, Alexander KP et al. 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol.* 2017 Mar 14;69(10):1313-1346.
23. Pison L, Potpara TS, Chen J et al. Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. *Europace.* 2015 Apr;17(4):642-646.
24. Schoenhagen P, Stillman AE, Halliburton SS et al. CT of the heart: principles, advances, clinical uses. *Cleve Clin J Med.* 2005 Feb;72(2):127-38.
25. Steiner J, Rodés-Cabau J, Holmes DR Jr et al. Mechanical Intervention for Aortic Valve Stenosis in Patients With Heart Failure and Reduced Ejection Fraction. *J Am Coll Cardiol.* 2017 Dec 19;70(24):3026-3041.
26. Taylor AJ, Cerqueira M, Hodgson JM et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. *Journal of the American College of Cardiology* 2010; 56 (22): 1864-1894.
27. Te Riele ASJM, Tandri H, Sanborn DM et al. Noninvasive Multimodality Imaging in ARVD/C. *JACC Cardiovasc Imaging.* 2015 May;8(5):597-611.
28. Thai WE, Wai B, Lin K et al. Pulmonary venous anatomy imaging with low-dose, prospectively ECG-triggered, high-pitch 128-slice dual-source computed tomography. *Circ Arrhythm Electrophysiol.* 2012 Jun 1;5(3):521-530.
29. White RD, Patel MR, Abbata S et al. 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: an executive summary: a joint report of the ACR Appropriateness Criteria® Committee and the ACCF Appropriate Use Criteria Task Force. 2013 Jul;10(7):493-500.
30. Wiant A, Nyberg E, Gilkeson RC. CT evaluation of congenital heart disease in adults. *AJR Am J Roentgenol.* 2009 Aug;193(2):388-396.

31. Wolk MJ, Bailey SR, Doherty JU et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Stable Ischemic Heart Disease A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. Journal of the American College of Cardiology 2013; 63 (4): 380-406.
32. Wolak A, Gransar H, Thomson LE et al. Aortic size assessment by noncontrast cardiac computed tomography: normal limits by age, gender, and body surface area. JACC Cardiovasc Imaging. 2008 Mar;1(2):200-209.
33. Wunderlich NC, Beigel R, Ho SY et al. Imaging for Mitral Interventions: Methods and Efficacy. JACC Cardiovasc Imaging. 2018 Jun;11(6):872-901.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 02/23/23.

GUIDELINE UPDATE INFORMATION:

05/15/18	New Medical Coverage Guideline.
11/15/19	Revised position statements for (cardiac structure and function/adult congenital heart disease, left ventricular function assessment, valvular assessment, intra and extracardiac structures, electrophysiologic procedure planning, transcatheter structural intervention planning, aortic pathology). Revised description, reimbursement information and abbreviations. Updated references.
04/15/20	Review/revision. Revised and expanded criteria for: adult congenital heart disease, left ventricular function assessment, valvular heart disease, intra and extracardiac structures, transcatheter structural intervention planning, and aortic pathology. Expanded criteria for: electrophysiologic procedure planning.
01/01/22	Annual CPT/HCPCS coding update. Revised 75573 code descriptor.
05/15/22	Revised and expanded criteria for: congenital heart disease and aortic pathology. Added indication and criteria for cardiomyopathy. Revised criteria for: valvular heart disease and electrophysiologic procedure planning, and transcatheter structural intervention planning. Updated program exceptions, abbreviations, and references.
07/01/22	Revision to Program Exceptions section.
09/30/23	Review: position statement and references updated.